CD8A and cancer: Exhausted CD8+ T cells are the major target of checkpoint blockade in patients with cancer and modulation of TOX, a transcription factor required for epigenetic remodeling and survival of functionally impaired exhausted T cells, has been suggested as a potential target for immunotherapy (63).